Ferritin-Based Mild Magnetic Hyperthermia Therapy for Bladder Cancer: A Synergistic Anti-Inflammatory Strategy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Bladder cancer treatment faces challenges including tissue damage, inflammation, and resistance to hyperthermia.
• Current magnetic hyperthermia (MH) therapies are limited by rapid nanoparticle clearance and poor tumor retention.

Purpose of the Study:

• To develop a mild MH strategy integrating pH-responsive magnetic ferritin and a glutathione-activated nitric oxide (NO) donor.
• To sensitize tumors to MH while minimizing off-target damage and improving therapeutic outcomes.

Main Methods:

• Utilized pH-responsive magnetic ferritin encapsulating Fe3O4 cores for heat generation via relaxation losses under alternating magnetic fields.
• Integrated NO gas therapy activated by glutathione within the tumor microenvironment.
• Evaluated the combined therapy's effects on tumor thermotolerance, immunosuppression, inflammation, and tumor regression.

Main Results:

• The ferritin shell ensured biocompatibility, enhanced tumor uptake, and captured byproducts, mitigating side effects.
• The combined MH and NO therapy weakened tumor thermotolerance and reversed the immunosuppressive tumor microenvironment.
• Demonstrated an abscopal effect and dampened NF-κB-mediated inflammatory signaling, leading to significant tumor regression.

Conclusions:

• This integrated approach achieves superior tumor regression and systemic tolerability compared to monotherapy.
• The strategy effectively combines tumor targeting, immunosuppression alleviation, and inflammation control for advanced hyperthermia therapy.
• Represents a promising advancement in MH for bladder cancer treatment.